Adjuvant treatment after resection of biliary-tract cancer: yes or no?

Biliary-tract cancers are rare tumors and carry poor prognosis despite some aggressive surgical approach. The benefit of adjuvant treatment is under debate, and except one there is no phase III trial available. However, it appears that, in a large proportion, adjuvant therapy is proposed to patient....

Full description

Bibliographic Details
Main Authors: Eveline Boucher, Marc Pracht, Catherine Le Roux, Karim Boudjema, Jean-Luc Raoul
Format: Article
Language:English
Published: PAGEPress Publications 2011-12-01
Series:Oncology Reviews
Subjects:
Online Access:http://www.oncologyreviews.org/index.php/or/article/view/60
id doaj-9cbd4e48c06d4bab8999fecc632f89ee
record_format Article
spelling doaj-9cbd4e48c06d4bab8999fecc632f89ee2020-11-25T03:41:08ZengPAGEPress PublicationsOncology Reviews1970-55571970-55652011-12-014310.4081/oncol.2010.16755Adjuvant treatment after resection of biliary-tract cancer: yes or no?Eveline Boucher0Marc Pracht1Catherine Le Roux2Karim Boudjema3Jean-Luc Raoul4Centre Eugène Marquis, Oncologie Médicale, RennesCentre Eugène Marquis, Oncologie Médicale, RennesCentre Eugène Marquis, Oncologie Médicale, RennesDépartement de Chirurgie viscérale, Centre Hospitalier Universitaire, RennesCentre Eugène Marquis, Oncologie Médicale, RennesBiliary-tract cancers are rare tumors and carry poor prognosis despite some aggressive surgical approach. The benefit of adjuvant treatment is under debate, and except one there is no phase III trial available. However, it appears that, in a large proportion, adjuvant therapy is proposed to patient. It could be chemotherapy or radiotherapy alone or both. Many publications are available on this topic. These are sometimes phase II studies, but mostly retrospective data about the experience of one center. All these studies have got many bias and the results must be interpreted with caution, even if patients could get some benefit of adjuvant therapy in case of adverse prognostic factors as positive resection margin and/or nodal involvement. In this review, we sum up the different therapies used as adjuvant treatment for biliary-tract cancer, and then we have studied what is done in clinical practice in order to propose a phase III clinical trial in this setting.http://www.oncologyreviews.org/index.php/or/article/view/60Adjuvant treatment - Surgery - Biliary-tract cancer
collection DOAJ
language English
format Article
sources DOAJ
author Eveline Boucher
Marc Pracht
Catherine Le Roux
Karim Boudjema
Jean-Luc Raoul
spellingShingle Eveline Boucher
Marc Pracht
Catherine Le Roux
Karim Boudjema
Jean-Luc Raoul
Adjuvant treatment after resection of biliary-tract cancer: yes or no?
Oncology Reviews
Adjuvant treatment - Surgery - Biliary-tract cancer
author_facet Eveline Boucher
Marc Pracht
Catherine Le Roux
Karim Boudjema
Jean-Luc Raoul
author_sort Eveline Boucher
title Adjuvant treatment after resection of biliary-tract cancer: yes or no?
title_short Adjuvant treatment after resection of biliary-tract cancer: yes or no?
title_full Adjuvant treatment after resection of biliary-tract cancer: yes or no?
title_fullStr Adjuvant treatment after resection of biliary-tract cancer: yes or no?
title_full_unstemmed Adjuvant treatment after resection of biliary-tract cancer: yes or no?
title_sort adjuvant treatment after resection of biliary-tract cancer: yes or no?
publisher PAGEPress Publications
series Oncology Reviews
issn 1970-5557
1970-5565
publishDate 2011-12-01
description Biliary-tract cancers are rare tumors and carry poor prognosis despite some aggressive surgical approach. The benefit of adjuvant treatment is under debate, and except one there is no phase III trial available. However, it appears that, in a large proportion, adjuvant therapy is proposed to patient. It could be chemotherapy or radiotherapy alone or both. Many publications are available on this topic. These are sometimes phase II studies, but mostly retrospective data about the experience of one center. All these studies have got many bias and the results must be interpreted with caution, even if patients could get some benefit of adjuvant therapy in case of adverse prognostic factors as positive resection margin and/or nodal involvement. In this review, we sum up the different therapies used as adjuvant treatment for biliary-tract cancer, and then we have studied what is done in clinical practice in order to propose a phase III clinical trial in this setting.
topic Adjuvant treatment - Surgery - Biliary-tract cancer
url http://www.oncologyreviews.org/index.php/or/article/view/60
work_keys_str_mv AT evelineboucher adjuvanttreatmentafterresectionofbiliarytractcanceryesorno
AT marcpracht adjuvanttreatmentafterresectionofbiliarytractcanceryesorno
AT catherineleroux adjuvanttreatmentafterresectionofbiliarytractcanceryesorno
AT karimboudjema adjuvanttreatmentafterresectionofbiliarytractcanceryesorno
AT jeanlucraoul adjuvanttreatmentafterresectionofbiliarytractcanceryesorno
_version_ 1724531519824855040